These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18693628)

  • 21. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Höfner K; Claes H; De Reijke TM; Folkestad B; Speakman MJ
    Eur Urol; 1999 Oct; 36(4):335-41. PubMed ID: 10473995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.
    Alan C; Kırılmaz B; Koçoğlu H; Ersay AR; Ertung Y; Eren AE
    Urology; 2011 Jun; 77(6):1439-43. PubMed ID: 21256572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.
    Yuan J; Liu Y; Yang Z; Qin X; Yang K; Mao C
    Curr Med Res Opin; 2013 Mar; 29(3):279-87. PubMed ID: 23323875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of medical treatments for benign prostatic hyperplasia on sexual function.
    Giuliano F
    BJU Int; 2006 Apr; 97 Suppl 2():34-8; discussion 44-5. PubMed ID: 16507052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review.
    Dong Z; Wang Z; Yang K; Liu Y; Gao W; Chen W
    Syst Biol Reprod Med; 2009 Aug; 55(4):129-36. PubMed ID: 19886768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacologic treatment of benign prostatic hyperplasia].
    Romics I
    Orv Hetil; 2003 Sep; 144(37):1809-14. PubMed ID: 14596018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
    Kaplan SA; Te AE; Ikeguchi E; Santarosa RP
    Br J Urol; 1997 Dec; 80(6):875-9. PubMed ID: 9439400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy of benign prostatic hyperplasia with alpha receptor blockers].
    Stockamp K
    Urologe A; 1995 Jan; 34(1):3-8. PubMed ID: 7533449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
    Wilde MI; Fitton A; McTavish D
    Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists.
    Milani S; Djavan B
    BJU Int; 2005 Jun; 95 Suppl 4():29-36. PubMed ID: 15871733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
    Beduschi MC; Beduschi R; Oesterling JE
    Urology; 1998 Jun; 51(6):861-72. PubMed ID: 9609620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha blockers: are all created equal?
    Debruyne FM
    Urology; 2000 Nov; 56(5 Suppl 1):20-2. PubMed ID: 11074198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being.
    de Mey C
    Eur Urol; 1998; 34 Suppl 2():18-28; discussion 47. PubMed ID: 9732825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
    Kyprianou N
    J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial.
    Lapitan MC; Acepcion V; Mangubat J
    J Int Med Res; 2005; 33(5):562-73. PubMed ID: 16222890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
    Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
    Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
    van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
    Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benign prostatic hyperplasia. Current pharmacological treatment.
    Jønler M; Riehmann M; Bruskewitz RC
    Drugs; 1994 Jan; 47(1):66-81. PubMed ID: 7510622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.